See more : Karnov Group AB (publ) (KAR.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Ibere Pharmaceuticals (IBER-UN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ibere Pharmaceuticals, a leading company in the Shell Companies industry within the Financial Services sector.
- Angkor Resources Corp. (ANKOF) Income Statement Analysis – Financial Results
- Atreca, Inc. (BCEL) Income Statement Analysis – Financial Results
- Beijing Yanjing Brewery Co.,Ltd. (000729.SZ) Income Statement Analysis – Financial Results
- Ace Ethanol LLC (ACEEU) Income Statement Analysis – Financial Results
- Aurora Acquisition Corp. (AURCW) Income Statement Analysis – Financial Results
Ibere Pharmaceuticals (IBER-UN)
About Ibere Pharmaceuticals
Ibere Pharmaceuticals does not have significant operations. It focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2020 and is based in Philadelphia, Pennsylvania.
Metric | 2021 |
---|---|
Revenue | 0.00 |
Cost of Revenue | 1.00M |
Gross Profit | -1.00M |
Gross Profit Ratio | 0.00% |
Research & Development | 0.00 |
General & Administrative | 0.00 |
Selling & Marketing | 0.00 |
SG&A | 0.00 |
Other Expenses | 1.00M |
Operating Expenses | 1.00M |
Cost & Expenses | 1.00M |
Interest Income | 17.12K |
Interest Expense | 0.00 |
Depreciation & Amortization | -2.55M |
EBITDA | -3.55M |
EBITDA Ratio | 0.00% |
Operating Income | -1.00M |
Operating Income Ratio | 0.00% |
Total Other Income/Expenses | 2.57M |
Income Before Tax | 1.56M |
Income Before Tax Ratio | 0.00% |
Income Tax Expense | -17.12K |
Net Income | 1.56M |
Net Income Ratio | 0.00% |
EPS | 0.34 |
EPS Diluted | 0.34 |
Weighted Avg Shares Out | 14.87M |
Weighted Avg Shares Out (Dil) | 14.87M |
Source: https://incomestatements.info
Category: Stock Reports